Sivendran S, Lynch S, McNaughton C, Wong R, Svetec S, Moore JH, Holliday R, Oyer RA, Newport K. Anticancer Therapy at the End of Life: Lessons From a Community Cancer Institute. , J Palliat Care., 36(2): 2021,87-92
Newport K, Sivendran S. Including the Oncologist in Palliative Oncology: A Response to Nature of Discussions about Systemic Therapy Discontinuation or Hospice among Patients, Families, and Palliative Care Clinicians during Care for Incurable Cancer: A Qualitative Study. , J Palliat Med. , 23(4): 2020,451-452
McNaughton CH, Horst M, Gehron E, Sivendran S, Nguyen J, Holliday R, Newport K. Patterns of Support Service, Emergency Department and Hospital Utilization in Patients with Advanced Cancer: A Descriptive Study. , J Palliat Care., 35(1): 2020,34-39
Finlay E, Newport K, Sivendran S, Kilpatrick L, Owens M, Buss MK Models of Outpatient Palliative Care Clinics for Patients With Cancer. , J Oncol Pract
, 15(4): 2019,187-193
Sivendran S, Jenkins S, Svetec S, Horst M, Newport K, Yost KJ, Yang M. Illness Understanding of Oncology Patients in a Community-Based Cancer Institute. , J Oncol Prac., 13(9): 2017,e800-e808.
Wyluda E, Newport K, Sauder M, Sivendran S. Safety and efficacy of vandetanib in the treatment of medullary thyroid cancer. , Journal of Signs and Symptoms, 3(2): 2016
Sivendran S, Galsky MD. Adverse event reporting in oncology clinical trials - lost in translation? , Expert Opin Drug Saf
, 15(7): 2016,893-6
Sivendran S, Holliday R, Guittar R, Cox C, Newport K The impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients. , Journal of Community and Supportive Oncology , 14(6): 2016,268-272
Perkins SH, Stensland KD, Galsky MD, Sivendran S. Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies. , Trials
, 16: 2015,341
Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. , Target Oncol., 9(3): 2014,195-204